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OBJECTIVES: To compare the economic costs and beneﬁts of
eszopiclone co-administered with ﬂuoxetine (ESZ+FLX) to that
of placebo co-administered with ﬂuoxetine (PBO+FLX) in
patients with insomnia and co-morbid MDD. METHODS:
Data from 422 patients enrolled in an 8-week, double-blind,
placebo-controlled, trial were used to estimate the cost per
quality-adjusted life-year (QALY) gained by treating patients’
insomnia with ESZ along with FLX for MDD. The costs of
medical care and time away from work were estimated using
published algorithms based on scores of the Hamilton Depres-
sion Scale (HAM-D17). Cost of lost productivity while at work
was based on responses to the Work Limitations Questionnaire
collected during the trial. Utilities were estimated via the HAM-
D17 scores or the SF-36 scores collected during the trial using
published transformation methods. Drug costs were estimated
based on average wholesale price, adjusted for standard dis-
counts and dispensing fees. All costs (in 2007 US$) and QALYs
were estimated using the 8-week trial data or the trial data
extrapolated to 6 months using last observation carried
forward. Treatment discontinuations before and after Week 8
were taken into consideration and sensitivity analysis of key
parameters was performed. RESULTS: In the base case 8-week
analysis using HAM-D17-derived utilities, the mean gains in
QALYs were 0.0392 and 0.0334 for the ESZ+FLX and
PBO+FLX groups, respectively. Mean 8-week per-patient costs
including absenteeism and presenteeism were $1,279 and
$1,198, respectively. Thus, eszopiclone with co-administered
ﬂuoxetine resulted in an incremental cost per QALY gained of
$13,881. When absenteeism and presenteeism costs were
excluded, this ratio increased to $29,748. The 6-month trial
data extrapolation, including productivity costs, resulted in
ESZ+FLX being a cost-saving, QALY-gaining strategy with a
cost/QALY of $13,911. CONCLUSIONS: Co-treatment of
insomnia with eszopiclone, and MDD with ﬂuoxetine appeared
to be economically advantageous for patients with patients
with both disorders.
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OBJECTIVES: To estimate changes in measures of hospitalisa-
tion use in a naturalistic clinical setting in Finland following
switch to Risperdal Consta, a long-acting atypical antipsy-
chotic. METHODS: Data were collected retrospectively from
patient charts at 10 geographically and functionally diverse
sites in Finland. Patients were at least 18 years old, diagnosed
with schizophrenia or schizoaffective disorder, and initiated
treatment with Risperdal Consta between January 1, 2004 and
June 30, 2005. The study employed a mirror-image design.
Two analyses were conducted: 1) Modiﬁed intention-to-treat
(ITT) analysis based on the complete observational dataset, and
2) Matched per-protocol analysis, with duration of pre-switch
patient data matched to the duration of Risperdal Consta treat-
ment follow-up. The main outcome measures are the change in
mean rate of hospitalisations per year between the pre- and
post-switch periods and change in mean annual number of days
in hospital. RESULTS: A total of 177 patients fulﬁlled the
inclusion criteria (mean age 47 years, 52% female, average
duration of schizophrenia 15 years). The most common reason
for switching to Consta was non-compliance on other medica-
tions (63%). Consta treatment continuation rates of at least 6,
12, 18 and 24 months were 76.6%, 70.9%, 68.0% and 66.2%,
respectively. The ITT analysis shows that switch to Consta was
associated with signiﬁcant reductions in number of hospitalisa-
tions per year (from 0.93 to 0.74) and in mean annual days in
hospital (from 62.9 to 38.0 days per patient-year of treatment),
corresponding to an estimated annual cost saving of €11,948
per patient. The matched per-protocol analysis shows larger
changes for all endpoints compared with the ITT analyses. All
changes were statistically signiﬁcant at the 95% conﬁdence
level. CONCLUSIONS: This study of 177 patients with schizo-
phrenia switching to long-acting Risperdal Consta indicates a
high treatment continuation rate and sizeable reductions in
inpatient resource use.
PMH23
THE ECONOMIC EFFECTS OF FASTERTITRATION AND
LOWER RELAPSE RATE OF QUETIAPINE XR COMPAREDTO
QUETIAPINE IR—THE ECONOMICVALUE OF A NEW DRUG
FORMULATION
Laine J1, Järbrink K2
1AstraZeneca, Espoo, Finland, 2AstraZeneca, Mölndal, Sweden
OBJECTIVES: The aim is to explore the economical beneﬁts of
quetiapine extended-release (XR) compared to quetiapine
immediate-release (IR) in treating patients with schizophrenia in
hospitals and outpatient care in the Finnish setting. The analysis
explores the effects of titration time and probability of relapse on
expected annual costs. METHODS: The analysis estimates the
total direct health care costs for a patient with schizophrenia over
a one-year time horizon. One-year probabilities of relapse were
derived from literature. Costs were gathered from national unit
cost report in 2007 and length of stay data was based on a
Finnish register study. Due to short-term perspective no discount-
ing was applied. In addition to deterministic approach, an Excel
based simulation model was used for the probabilistic analyses
and one-way sensitivity analyses. RESULTS: Total costs in
average were €25,687 and €26,736 for patients treated by que-
tiapine XR and quetiapine IR, respectively. The results of the
stochastic model indicated that quetiapine XR was associated
with cost savings of €1300 per patient per year. Most sensitive
parameters were length of inpatient periods and unit cost of
quetiapine IR. Approximately 94% of the saving was due to
effects of faster titration and 6% due to difference in relapse
rates. CONCLUSIONS: The results of this model suggest that
expected total costs for patients treated with quetiapine XR are
lower than for patients treated with quetiapine IR. The potential
increase in hospital drug budgets due to introduction of quetiap-
ine XR may be offset by lower inpatient care costs associated
with quetiapine XR.
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